Literature DB >> 3119349

Experimental Trypanosoma brucei infections selectively suppress both interleukin 2 production and interleukin 2 receptor expression.

M Sileghem1, R Hamers, P De Baetselier.   

Abstract

Experimental infections with Trypanosoma brucei AnTat 1.1.E not only account for a suppression of interleukin 2 (IL 2) production, but also induce an impairment of IL 2 receptor expression. Indeed, lymph node cells derived from infected mice failed to express IL 2 receptors following mitogenic stimulation as compared to normal controls. This impairment was not attributed to a modulation of the number of T cells and was not caused by the presence of living parasites. Furthermore, the basal level of IL 2 receptor expression could not be re-established through the exogenous supply of recombinant IL 2. This impairment of receptor expression was found to be mediated by suppressive cells that affect the relative number of receptor-positive cells as well as the mean receptor density. On the other hand, the mitogen-induced secretion of other T cell-derived lymphokines was not inhibited during infection, indicating that the severe suppression of IL 2 regulation was not attributed to a total paralysis of the T cell responsiveness.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3119349     DOI: 10.1002/eji.1830171005

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  11 in total

1.  A soluble factor from Trypanosoma brucei rhodesiense that prevents progression of activated human T lymphocytes through the cell cycle.

Authors:  M B Sztein; F Kierszenbaum
Journal:  Immunology       Date:  1991-06       Impact factor: 7.397

2.  In vitro simulation of immunosuppression caused by Trypanosoma brucei.

Authors:  M Sileghem; A Darji; P De Baetselier
Journal:  Immunology       Date:  1991-06       Impact factor: 7.397

3.  In vitro simulation of immunosuppression caused by Trypanosoma brucei: active involvement of gamma interferon and tumor necrosis factor in the pathway of suppression.

Authors:  A Darji; A Beschin; M Sileghem; H Heremans; L Brys; P De Baetselier
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

4.  Immunopathology of experimental African sleeping sickness: detection of cytokine mRNA in the brains of Trypanosoma brucei brucei-infected mice.

Authors:  C A Hunter; J W Gow; P G Kennedy; F W Jennings; M Murray
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

5.  Tsetse fly saliva accelerates the onset of Trypanosoma brucei infection in a mouse model associated with a reduced host inflammatory response.

Authors:  Guy Caljon; Jan Van Den Abbeele; Benoît Stijlemans; Marc Coosemans; Patrick De Baetselier; Stefan Magez
Journal:  Infect Immun       Date:  2006-09-05       Impact factor: 3.441

6.  Modulation of IL-1 production and IL-1 release during experimental trypanosome infections.

Authors:  M Sileghem; A Darji; R Hamers; P De Baetselier
Journal:  Immunology       Date:  1989-09       Impact factor: 7.397

7.  Suppression by Trypanosoma cruzi of T-cell receptor expression by activated human lymphocytes.

Authors:  M B Sztein; F Kierszenbaum
Journal:  Immunology       Date:  1992-10       Impact factor: 7.397

8.  Suppression by Trypanosoma brucei rhodesiense of the capacities of human T lymphocytes to express interleukin-2 receptors and proliferate after mitogenic stimulation.

Authors:  F Kierszenbaum; S Muthukkumar; L A Beltz; M B Sztein
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

9.  T cells and macrophages in Trypanosoma brucei-related glomerulopathy.

Authors:  M L van Velthuysen; A E Mayen; N van Rooijen; G J Fleuren; E de Heer; J A Bruijn
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

10.  Inhibition of T-cell responsiveness during experimental infections with Trypanosoma brucei: active involvement of endogenous gamma interferon.

Authors:  A Darji; M Sileghem; H Heremans; L Brys; P De Baetselier
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.